Sandbox: malabsorption: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 6: | Line 6: | ||
{| style="border: 0px; font-size: 100%; margin: 3px;" align="center" | {| style="border: 0px; font-size: 100%; margin: 3px;" align="center" | ||
! rowspan=" | ! rowspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause | ||
| colspan="9" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestation''' | | colspan="9" style="background:#4479BA; color: #FFFFFF;" align="center" |'''Clinical manifestation''' | ||
! colspan=" | ! colspan="9" rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Lab findings | ||
! rowspan=" | ! rowspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |Extra intestinal findings | ||
! rowspan=" | ! rowspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |Cause/Pathogenesis | ||
! rowspan=" | ! rowspan="5" style="background:#4479BA; color: #FFFFFF;" align="center" |Gold standard diagnosis | ||
|- | |- | ||
! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | ! colspan="8" style="background:#4479BA; color: #FFFFFF;" align="center" |Symptoms | ||
! rowspan=" | ! rowspan="4" style="background:#4479BA; color: #FFFFFF;" align="center" |GI signs | ||
|- | |- | ||
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Duration | ! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" |Duration | ||
! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ! colspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Diarrhea | ||
! rowspan=" | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Fever | ||
! rowspan=" | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Abdominal pain | ||
! rowspan=" | ! rowspan="3" style="background:#4479BA; color: #FFFFFF;" align="center" |Weight loss | ||
! | |||
|- | |||
! | |||
! | |||
! | |||
! | |||
! | |||
! colspan="3" |CBC | |||
! colspan="5" |Stool exam | |||
! | ! | ||
|- | |- | ||
Line 31: | Line 40: | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Hgb | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Hgb | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Plt | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Plt | ||
! style="background:#4479BA; color: #FFFFFF;" align="center" | | !WBC | ||
!RBC | |||
!Ova/Parasite | |||
!Osmotic gap | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other | |||
! style="background:#4479BA; color: #FFFFFF;" align="center" |Other lab findings | ! style="background:#4479BA; color: #FFFFFF;" align="center" |Other lab findings | ||
|- | |- | ||
Line 49: | Line 62: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓/↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓/↑ | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 85: | Line 102: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 119: | Line 140: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 147: | Line 172: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 177: | Line 206: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↑ | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 210: | Line 243: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 241: | Line 278: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 273: | Line 314: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 298: | Line 343: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 326: | Line 375: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 353: | Line 406: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 381: | Line 438: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 418: | Line 479: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 451: | Line 516: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | | ||
Line 480: | Line 549: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 501: | Line 574: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 536: | Line 613: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 568: | Line 649: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↑ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | ↑ | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 601: | Line 686: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 633: | Line 722: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |↓ | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 661: | Line 754: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | - | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 688: | Line 785: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 707: | Line 808: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 726: | Line 831: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 745: | Line 854: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 764: | Line 877: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 783: | Line 900: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 802: | Line 923: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| | |||
| | |||
| | |||
| | |||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" | | | style="padding: 5px 5px; background: #F5F5F5;" align="center" | | ||
Line 823: | Line 948: | ||
!↓ | !↓ | ||
!↓ | !↓ | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
* Enzyme immunoassay (EIA) for ''C difficile'' toxin A and B | * Enzyme immunoassay (EIA) for ''C difficile'' toxin A and B | ||
Line 843: | Line 972: | ||
* CT | * CT | ||
|- | |- | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! | ||
Line 862: | Line 995: | ||
! | ! | ||
|- | |- | ||
! | |||
! | |||
! | |||
! | |||
! | ! | ||
! | ! |
Revision as of 04:40, 5 December 2017
Diarrhea
Abbreviations: GI: Gastrointestinal; WBC: White blood cells; Plt: Platelets, Hgb: Hemoglobin, IgE: Immunoglobulin E, IgA: Immunoglobulin A
Cause | Clinical manifestation | Lab findings | Extra intestinal findings | Cause/Pathogenesis | Gold standard diagnosis | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | GI signs | ||||||||||||||||||||
Duration | Diarrhea | Fever | Abdominal pain | Weight loss | |||||||||||||||||
CBC | Stool exam | ||||||||||||||||||||
Acute | Chronic | Watery | Bloody | Fatty | WBC | Hgb | Plt | WBC | RBC | Ova/Parasite | Osmotic gap | Other | Other lab findings | ||||||||
Whipple's disease | + | - | + | ± | + | + | ↓ | ↓ | ↓/↑ |
| |||||||||||
Celiac disease | ± | - | ± | - | + | + | - | ↓ | - |
|
|
|
|||||||||
Tropical sprue | + | - | + | + | + | + |
|
- | ↓ | - |
|
| |||||||||
Crohns disease | + | + | + | + | + | + | ↑ | ↓ | ↑ |
|
|
|
| ||||||||
Ulcerative colitis | + | + | + | + | + | + | ↑ | ↓ | ↑ |
|
|
| |||||||||
Cystic fibrosis | - | - | + | ± | + | + | - | ↓ | - |
|
|
| |||||||||
VIPoma | + | - | + | - | + | + |
|
- | - | - |
|
|
| ||||||||
Zollinger-Ellison syndrome | + | - | + | - | + | + | - | ↓ | - |
|
| ||||||||||
Eosinophilic gastroenteritis | + | - | + | - | + | + | ↑ | - | - |
|
|
|
| ||||||||
Primary bile acid malabsorption | + | - | + | - | + | + | - | ↓ | - |
|
|
| |||||||||
Abetalipoproteinemia | + | - | + | - | + | + | - | - | - |
|
|
|
| ||||||||
Microscopic colitis | + | + | - | - | + | + | - | ↓ | - |
|
|
|
| ||||||||
Hyperthyroidism | + | - | - | ± | + | + | - | - | - |
|
|||||||||||
Lactose intolerance | + | - | - | - | + | - | - | - | - |
|
|
| |||||||||
Irritable bowel syndrome | ± | - | ± | - | ± | - |
|
- | - | - |
| ||||||||||
Chronic pancreatitis | + | - | + | - | + | + | - | - | - |
|
|
||||||||||
Cirrhosis | + | - | + | + | + | + |
|
↓ | ↓ | ↓ |
|
|
|
| |||||||
Short bowel syndrome | + | - | + | - | - | + |
|
- | ↓ | ↑ |
|
|
|
||||||||
Small bowel bacterial overgrowth | + | - | + | - | + | + | - | ↓ | - |
|
|
| |||||||||
X-linked agammaglobulinemia | + | - | + | + | + | + |
|
↓ | ↓ | - |
|
|
|
| |||||||
Intestinal lymphangiectasia | - | - | + | - | - | + |
|
↓ | - | - |
|
|
|
Intestinal biopsy | |||||||
Amyloidosis | + | ||||||||||||||||||||
Mastocytosis | |||||||||||||||||||||
Drug induced enteritis | |||||||||||||||||||||
Giardiasis | + | ||||||||||||||||||||
Strongyloidiasis | |||||||||||||||||||||
Tuberculosis | |||||||||||||||||||||
Chronic laxative abuse | |||||||||||||||||||||
Pseudomembranous colitis | + | - | + | +/- | - | + | + | +/- |
|
↑ | ↓ | ↓ |
|
|
|
| |||||